Publicacions en col·laboració amb investigadors/es de Marche Polytechnic University (28)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2023

  1. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

    JAMA dermatology, Vol. 159, Núm. 8, pp. 837-847

  2. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

    Rheumatology (Oxford, England), Vol. 62, Núm. 4, pp. 1559-1567

  3. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: A EUSTAR database analysis

    Rheumatology (United Kingdom), Vol. 62, Núm. 7, pp. 2483-2491

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

    The Lancet Rheumatology, Vol. 4, Núm. 11, pp. e785-e794

2021

  1. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 213-222

  2. The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort

    Swiss medical weekly, Vol. 151, pp. w20528

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

    The Lancet Rheumatology, Vol. 2, Núm. 2, pp. e71-e83

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  3. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

2018

  1. There is a need for new systemic sclerosis subset criteria. A content analytic approach

    Scandinavian Journal of Rheumatology, Vol. 47, Núm. 1, pp. 62-70

2017

  1. Overexpression of the cytokine BAFF and autoimmunity risk

    New England Journal of Medicine, Vol. 376, Núm. 17, pp. 1615-1626

  2. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 8, pp. 1521-1526

2015

  1. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

    Microvascular Research, Vol. 102, pp. 19-24

  2. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database

    Clinical and Experimental Rheumatology, Vol. 33, pp. 47-54